• Eisai flagged new clinical and real-world analyses for LENVIMA that will be presented at the ASCO 2026 meeting in Chicago from May 29 to June 2.
• A real-world study in BRAF-mutated differentiated thyroid cancer will compare first-line LENVIMA with dabrafenib and trametinib to inform treatment choice in routine practice.
• A separate analysis from the Phase 3 CLEAR trial will assess how patients with advanced renal cell carcinoma fared on LENVIMA with pembrolizumab based on how their disease progressed, sharpening the evidence package for the regimen in the first-line setting.
• Eisai also highlighted an online ASCO publication from Phase 1 trials of pipeline drug E7386 focused on cardiac safety, supporting early-stage development decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605200808PR_NEWS_USPR_____NY63134) on May 20, 2026, and is solely responsible for the information contained therein.